Elevated baseline serum PD-1 or PD-L1 predicts poor outcome of PD-1 inhibition therapy in metastatic melanoma期刊界 All Journals 搜尽天下杂志传播学术成果专业期刊搜索期刊信息化学术搜索

Elevated baseline serum PD-1 or PD-L1 predicts poor outcome of PD-1 inhibition therapy in metastatic melanoma

Affiliation:	1. Department of Dermatology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany;2. German Consortium of Translational Cancer Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany;3. Translational Skin Cancer Research, German Consortium of Translational Cancer Research (DKTK), Essen, Germany;4. Institute for Transfusion Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany;5. Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg and Department of Dermatology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, Germany;6. Department of Dermatology, Saarland University Medical Center, Homburg/Saar, Germany;7. Department of Dermatology, Helios Klinikum Erfurt, Erfurt, Germany;8. Department of Dermatology, University Hospital Würzburg, Würzburg, Germany;9. Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands

Abstract:

Keywords:	anti-BRAF therapy anti-PD-1 therapy checkpoint inhibition melanoma PD-1 PD-L1
本文献已被 ScienceDirect 等数据库收录！